Your browser version may not work well with NCBI's Web applications. More information here...
1: Arthritis Res Ther. 2003;5(4):180-91. Epub 2003 May 29.Click here to read Click here to read Links

Wegener's granulomatosis: current and upcoming therapies.

Langford CA.

Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. clangford@niaid.nih.gov

Wegener's granulomatosis is a complex multisystem disease that can be associated with morbidity and mortality. The introduction of cyclophosphamide and glucocorticoids brought about the potential for long-term survival and provided the opportunity and impetus to explore treatment options that can reduce the toxicity of therapy and lessen the likelihood of relapse. With the growth of knowledge regarding disease pathophysiology and the increasing ability to selectively target the immune system, the potential options for therapeutic investigation have continued to expand. Careful study of new agents through rigorously designed trials is essential to answering questions of safety and efficacy in Wegener's granulomatosis.

PMID: 12823849 [PubMed - indexed for MEDLINE]

PMCID: PMC165064

Patient Drug Information

  • Cyclophosphamide (Cytoxan® , Neosar® )

    Your doctor has ordered the drug cyclophosphamide to help treat your illness. The drug can be taken by mouth in tablet form or be given by injection into a vein.

  • Source: AHFS Consumer Medication Information